

## The prevalence of carbapenemase genes and plasmid-mediated quinolone resistance determinants in carbapenem-resistant Enterobacteriaceae from five teaching hospitals in central China

L. HU<sup>1</sup>†, Q. ZHONG<sup>1</sup>†, Y. SHANG<sup>2</sup>, H. WANG<sup>1</sup>, C. NING<sup>1</sup>, Y. LI<sup>3</sup>,  
Y. HANG<sup>1</sup>, J. XIONG<sup>1</sup>, X. WANG<sup>1</sup>, Y. XU<sup>3</sup>, Z. QIN<sup>4</sup>, C. PARSONS<sup>4</sup>, L. WANG<sup>3</sup>\*  
AND F. YU<sup>2</sup>\*

<sup>1</sup> Department of Laboratory Medicine, Second Affiliated Hospital of Nanchang University, Nanchang, China

<sup>2</sup> Department of Laboratory Medicine, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China

<sup>3</sup> Department of Respiratory Medicine, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China

<sup>4</sup> Departments of Medicine and Microbiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA

Received 17 September 2013; Final revision 1 November 2013; Accepted 1 November 2013;  
first published online 20 November 2013

### SUMMARY

We investigated the prevalence of  $\beta$ -lactamase genes and plasmid-mediated quinolone resistance (PMQR) determinants in 51 carbapenem-resistant Enterobacteriaceae (CRE) from five teaching hospitals in central China. The prevalence of carbapenem resistance in Enterobacteriaceae was 1·0% (51/5012). Of 51 CRE, 31 (60·8%) isolates were positive for one tested carbapenemase gene, while 10 (19·6%) were simultaneously positive for two tested carbapenemase genes. The positive rates of *bla*<sub>KPC-2</sub>, *bla*<sub>NDM-1</sub>, *bla*<sub>IMP-4</sub>, *bla*<sub>IMP-26</sub> and *bla*<sub>IMP-8</sub> were 54·9%, 17·6%, 11·8%, 11·8% and 3·9%, respectively. Of 10 CRE with two carbapenemase genes, three, five, one and one were positive for *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-4</sub>, *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-26</sub>, *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-8</sub>, and *bla*<sub>KPC-2</sub> and *bla*<sub>NDM-1</sub>, respectively. Eight of nine *bla*<sub>NDM-1</sub>-positive isolates lacked carbapenemases by the modified Hodge test, while 27/28 isolates harbouring *bla*<sub>KPC-2</sub> were positive for carbapenemases determined by this test; 41·2% of the CRE-positive isolates also harboured ESBL genes in various combinations (three and two positive for *bla*<sub>KPC-2</sub> also carried *bla*<sub>DHA-1</sub> and *bla*<sub>CMY-2</sub>). The positive rates of *qnrS1*, *qnrA1*, *qnrB* and *aac*-(6)-*Ib-cr* in CRE were 25·5%, 9·8%, 23·5% and 15·7%, respectively. In particular, 7/9 isolates harbouring *bla*<sub>NDM-1</sub> were positive for these quinolone resistance genes, of which five carried *qnrS1* and two carried *qnrS1* and *qnrB4*. All but two of 29 *Klebsiella pneumoniae* isolates were grouped into 20 clonal clusters by PFGE, with the predominant cluster accounting for four *bla*<sub>KPC-2</sub>-positive isolates distributed in the same hospital. We conclude that there is a high prevalence of *bla*<sub>NDM-1</sub> and PMQR determinants in CRE isolates in central China. Multiple resistance determinants in various combinations co-exist in these strains and we report for the first time the co-existence of *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-26</sub> in a strain of *Klebsiella oxytoca*.

**Key words:** Carbapenemases, Enterobacteriaceae, quinolone resistance determinants.

\* Author for correspondence: Dr F. Yu, Department of Laboratory Medicine, First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.

(Email: wzxyfy@163.com) [F. Yu]

(Email: 38805@163.com) [L. Wang]

† These authors contributed equally to this work.

## INTRODUCTION

Multidrug resistance (MDR) in Enterobacteriaceae is a serious threat to public health as it limits the selection of antimicrobials for empirical treatment of infections caused by Gram-negative organisms [1]. Carbapenems are effective agents for the treatment of clinical infections caused by MDR Enterobacteriaceae; however, resistance of these organisms to these agents has been increasingly associated with production of carbapenemases, loss of porins, and expression of  $\beta$ -lactamases such as extended-spectrum  $\beta$ -lactamases (ESBLs) or AmpC enzymes [1]. *Klebsiella pneumoniae* carbapenemases (KPCs), especially KPC-2, are widespread in Enterobacteriaceae [2] and the Ambler class B metallo- $\beta$ -lactamases (MBLs), including IMP and VIM, are commonly harboured by non-fermentative bacteria and, more recently, in Enterobacteriaceae worldwide [3]. More specifically, global dissemination of the emerging New Delhi MBL (NDM), first identified in a clinical urinary tract isolate of *K. pneumoniae* is becoming a major public health issue [4–7] as this determinant has spread and is found in many Gram-negative species in several countries [4–9]. In China, NDM-1 was first identified from clonally unrelated *Acinetobacter baumannii* isolates [10] and subsequently, several reports have identified it in non-*baumannii* *Acinetobacter* spp. in China [11–13]. We reported the first NDM-1 isolate of *K. pneumoniae* from the Chinese mainland [14] and recently, the expression of multiple carbapenemases such as KPC-2 with IMP-4 in *K. pneumoniae* has been reported [7, 15–18] as well as with carbapenemases in other Enterobacteriaceae and *Acinetobacter* spp. [7, 15–17]. Indeed, carbapenemase genes are able to co-exist with several other resistance genes including ESBL, plasmid-mediated AmpC, plasmid-mediated quinolone resistance (PMQR), and plasmid-mediated aminoglycoside resistance determinants which implies acquisition of MDR by carbapenem-resistant Enterobacteriaceae (CRE) in hospital and community settings [19, 20].

The aim of the present study was to investigate antimicrobial resistance profiles and co-existence of resistance determinants in CRE isolates from five teaching hospitals in central China and to assess the epidemiological relatedness of carbapenem-resistant *K. pneumoniae* isolates within this cohort. We found a high co-prevalence of  $\beta$ -lactamase genes and PMQR determinants in CRE, and we provide the

first documentation of co-existence for *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-26</sub> in a single CRE isolate.

## MATERIALS AND METHODS

### Isolation and identification of isolates

From January 2011 to September 2012, a total of 5012 isolates of Enterobacteriaceae were recovered from clinical specimens collected from hospitalized patients in five teaching hospitals, including four in Nanchang, central China and one in Jiujiang (170 km north of Nanchang). Fifty-one (1.0%) isolates with resistance to at least one of ertapenem, imipenem and meropenem were defined as CRE. These CRE isolates originated from participants at different locations as follows: the first, second, third and fourth affiliated hospitals of Nanchang University (respectively hospital A, 17 isolates; hospital B, 25 isolates; hospital C, three isolates; hospital D, 4 isolates), and the affiliated hospital of Jiujiang College in Jiujiang (hospital E, two isolates). Identification was performed using a Vitek-32 automated microbiology analyser (bioMérieux, France) according to the manufacturer's instructions, as well as additional standard biochemical testing. Only bacterial isolates comprising  $>10^7$  c.f.u./ml by semi-quantitative culture from sputum specimens were considered significant and analysed in this study.

### Antimicrobial susceptibility

Antimicrobial susceptibilities were determined using Gram-negative susceptibility cards in the Vitek system (bioMérieux) and by disc diffusion in accordance with the guidelines recommended by Clinical and Laboratory Standards Institute (CLSI) [21]. The antimicrobials were ampicillin, piperacillin, piperacillin/tazobactam, cefotaxime, ceftazidime, cefepime, aztreonam, ceftazidime, imipenem, meropenem, trimethoprim/sulfamethoxazole, amikacin, gentamicin and levofloxacin. Results of susceptibility tests were interpreted according to the criteria recommended by CLSI [21]. *Escherichia (Es.) coli* ATCC 25922 was used as quality control strain.

### Detection of antimicrobial resistance determinants

The modified Hodge test (MHT) was performed for detection of carbapenemases as described previously [21] and for ESBL production by the the CLSI-recommended confirmatory double-disk combination

test [21]. Genes encoding carbapenemases, ESBL genes, plasmid-mediated AmpC and PMQR determinants were detected using polymerase chain reaction (PCR) and nucleotide sequencing employing previously published primers [22–24].

### Pulsed-field gel electrophoresis (PFGE)

Genomic DNA from *K. pneumoniae* isolates was prepared for PFGE typing and cleaved with 40 U *Xba*I. Electrophoresis was performed on 1% agarose gels in 0.5 M Tris/borate/EDTA buffer on a CHEF-Mapper XA PFGE system (Bio-Rad, USA) for 24 h at 14 °C, with run conditions of 6 V/cm, a pulse angle of 120° and pulse times from 5 s to 20 s. Bands were stained with ethidium bromide (0.5 µg/ml) prior to their identification under UV light. Comparison of the PFGE patterns was performed with Bionumerics software (Applied Maths, Belgium) using the Dice similarity coefficient. Clusters were defined as DNA patterns sharing >85% similarity.

## RESULTS AND DISCUSSION

The 51 CRE identified were by species, *K. pneumoniae* (29), *Enterobacter cloacae* (8), *K. oxytoca* (6), *Es. coli* (4), *K. ozaenae* (2), *Proteus mirabilis* (1) and *Citrobacter freundii* (1). The positive rates of carbapenem resistance in various species of Enterobacteriaceae were as follows: *K. pneumoniae*, 2.8% (29/1023); *E. cloacae*, 1.5% (8/523); *K. oxytoca*, 1.4% (6/427), *Es. coli*, 0.2% (4/2253), *K. ozaenae*, 3.4% (2/58), *P. mirabilis*, 0.8% (1/128) and *C. freundii*, 1.3% (1/78). These organisms were recovered from sputum (31), urine (5), exudates (4), pus (5), blood (5) and one from a central venous catheter tip. All CRE isolates were resistant to ampicillin and piperacillin. The resistance rates to other antimicrobials were as follows: piperacillin/tazobactam (82.4%), ceftazidime (98.0%), cefotaxime (96.1%), cefepime (94.1%); aztreonam (94.1%), ceftoxitin (90.2%), levofloxacin (76.5%), amikacin (43.1%), gentamicin (80.4%) and trimethoprim/sulfamethoxazole (76.5%). All but two of the 51 CRE isolates were resistant to multiple antimicrobials and (84.3%) were susceptible to at least one drug.

A total of 31 (60.8%) CRE isolates expressed carbapenemases based on the MHT and carriage of carbapenemase genes, including *bla*<sub>NDM-1</sub>, was investigated further using PCR and DNA sequencing. Most (80.4%) isolates expressed carbapenemase genes and

similar to previous reports on Enterobacteriaceae in China [25, 26], 54.9% of the isolates in this study harboured *bla*<sub>KPC-2</sub>. In China, *bla*<sub>NDM-1</sub> expression has been identified mainly for *Actinobacter* spp. [10–13] but the gene has been noted in Enterobacteriaceae in the country, albeit with a relatively low prevalence thus far [27]. We recently reported that two unrelated *K. pneumoniae* isolates harboured *bla*<sub>NDM-1</sub> [14, 28] and it was unexpected to find such a high prevalence (17.6%) of this gene in CRE in this study. The nine isolates expressing *bla*<sub>NDM-1</sub> included five *K. pneumoniae*, two *K. ozaenae*, one *K. oxytoca* and one *Es. coli*, indicating that the gene has been disseminated in Enterobacteriaceae in China. This should be a cause for concern for clinicians, microbiologists and administrators for infection control measures. Interestingly, all but one of the *bla*<sub>NDM-1</sub>-positive isolates were negative for carbapenemases by the MHT, while 27/28 isolates harbouring *bla*<sub>KPC-2</sub> were positive by this method, indicating that the test is not suitable for the detection of NDM-1 production. The MHT has excellent sensitivity for detection of enterobacterial isolates producing KPC- and OXA-48-type carbapenemases, but has low sensitivity for NDM-1 producers [28], which is further supported by a previous study which reported negative or weakly positive MHT results for 11/15 NDM-1-producing strains [29]; therefore, it is important for clinical laboratories to develop sensitive methods for identifying such strains.

In addition to KPC-2 and NDM-1, IMP-type metallo-β-lactamases also contribute to carbapenem resistance in Enterobacteriaceae. In the present study, 14 CRE isolates expressed *bla*<sub>IMP</sub>, including *bla*<sub>IMP-4</sub> (6), *bla*<sub>IMP-26</sub> (6) and *bla*<sub>IMP-8</sub> (2) but all were negative for *bla*<sub>VIM</sub>. Co-production of different carbapenemases was also found in clinically important organisms, which poses a challenge for infection control [7, 15–18]. We found that 10 isolates simultaneously harboured two carbapenemase genes in various combinations as follows: one isolate each of *K. pneumoniae*, *E. cloacae* and *K. oxytoca* had both *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-4</sub>; three *K. pneumoniae* and two *E. cloacae* isolates had both *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-26</sub>; one *C. freundii* isolate harboured both *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-8</sub>; and a single *K. oxytoca* isolate harboured both *bla*<sub>KPC-2</sub> and *bla*<sub>NDM-1</sub>. Co-existence of *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-4</sub> has previously been documented in *K. pneumoniae* [18, 30], and co-existence of *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-8</sub> was first identified in a *K. oxytoca* isolate from Shanghai, east China [31]. Recently, NDM-1




Fig. 1. Dendrogram of patterns for carbapenem-resistant *K. pneumoniae* isolates obtained by pulsed-field gel electrophoresis.

was also found to co-exist with other carbapenemases, including OXA-23, KPC-2, IMP-26 and OXA-181 [7, 15–17, 27]. To the best of our knowledge, the present study is the first to report co-existence of *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-26</sub> in *K. pneumoniae* and *E. cloacae* isolates as well as the co-existence of *bla*<sub>KPC-2</sub> and *bla*<sub>NDM-1</sub> in *K. oxytoca*. The 10 CRE isolates not expressing carbapenemase genes by PCR harboured at least one ESBL gene and/or plasmid-mediated AmpC gene. Carbapenem resistance in these isolates may therefore be associated with other carbapenemases not examined in this study, or other resistance mechanisms including loss of porins and efflux pumps.

Co-production of carbapenemases with other  $\beta$ -lactamases results in resistance to nearly all clinically available  $\beta$ -lactams. Since AmpCs and carbapenemases are not inhibited by clavulanic acid, co-production of ESBLs, AmpCs and carbapenemases can mask identification of ESBLs by the CLSI-recommended double-disk test. Detection of multiple  $\beta$ -lactamases produced by Enterobacteriaceae in the clinical laboratory is therefore challenging. In the present study, although ESBL genes were expressed by 62.7% (32/51) of CRE isolates, only 29.4% (15/51) were found to produce ESBLs as determined by the CLSI-recommended double-disk test. Of 32 isolates with ESBL genes, 25 carried

*bla*<sub>CTX-M</sub>, including *bla*<sub>CTX-M-3</sub> (6), *bla*<sub>CTX-M-14</sub> (5), *bla*<sub>CTX-M-15</sub> (6), both *bla*<sub>CTX-M-9</sub> and *bla*<sub>CTX-M-3</sub> (4), *bla*<sub>CTX-M-65</sub> (2), *bla*<sub>CTX-M-9</sub> (1) and *bla*<sub>CTX-M-84</sub> (1). Thirty (58.8%) CRE isolates harboured *bla*<sub>SHV</sub> and comprised 13 isolates with SHV-type ESBL genes, including *bla*<sub>SHV-12</sub> (10), *bla*<sub>SHV-5</sub> (1), *bla*<sub>SHV-28</sub> (1) and *bla*<sub>SHV-36</sub> (1). The remaining 17 *bla*<sub>SHV</sub>-positive isolates carried SHV-type narrow spectrum  $\beta$ -lactamase genes, including *bla*<sub>SHV-11</sub> (8) and *bla*<sub>SHV-1</sub> (9). *bla*<sub>TEM</sub> was detected in 60.8% (31/51) CRE isolates, and all *bla*<sub>TEM</sub> amplicons were identified as the narrow spectrum  $\beta$ -lactamase gene, *bla*<sub>TEM-1</sub>. Co-existence of *bla*<sub>SHV</sub>- and *bla*<sub>CTX-M</sub>-type ESBL genes was identified for six CRE isolates. Twenty-one (41.2%) of the CRE isolates with carbapenemase genes based on PCR also harboured ESBL genes in various combinations, and 21 (41.2%) also expressed AmpCs as determined by the three-dimension test. Thirteen (25.5%) isolates were positive for plasmid-mediated AmpC genes, including *bla*<sub>DHA-1</sub> (6), *bla*<sub>CMY-2</sub> (5), *bla*<sub>MIR-3</sub> (1) and *bla*<sub>ACT-16</sub> (1). Isolates expressing *bla*<sub>KPC-2</sub> simultaneously harboured *bla*<sub>DHA-1</sub> (3) and *bla*<sub>CMY-2</sub> (2). No plasmid-mediated AmpC genes were detected in *bla*<sub>NDM-1</sub>-positive isolates.

Although PMQR determinants alone may not confer resistance to quinolones, they do supplement other quinolone resistance mechanisms. In China, PMQR

determinants, especially *aac*-(6′)-*Ib-cr*, have been found in Enterobacteriaceae clinical isolates [32]. In the present study, 32 (62.7%) of 51 CRE isolates expressed PMQR determinants, including *qnrS1* (11), *qnrA1* (4), *qnrB2* (2), *qnrB4* (6), *qnrB10* (1), both *qnrS1* and *qnrB4* (2), both *qnrA1* and *qnrB1* (1) and *aac*-(6′)-*Ib-cr* (5). Two isolates with *qnrS1* and one isolate with *qnrB4* were positive for *aac*-(6′)-*Ib-cr*. The positive rates for *qnrS1*, *qnrA1*, *qnrB* and *aac*-(6′)-*Ib-cr* were 25.5% (13/51), 9.8% (5/51), 23.5% (12/51) and 15.7% (8/51), respectively. Of 41 CRE isolates expressing carbapenemase genes, the prevalence of PMQR determinants was 65.8% (27/41). Specifically, 77.8% (7/9) of isolates harbouring *bla*<sub>NDM-1</sub> expressed PMQR genes, including *qnrS1* (5), and both *qnrS1* and *qnrB4* (2). In a previous study from China, *qnr* genes were expressed by 67.5% (27/40) of KPC-2-producing *K. pneumoniae* isolates [19]. Co-existence of carbapenemase genes and PMQR determinants contributes to MDR.

Of 29 *K. pneumoniae* CRE isolates, 27 were successfully typed and grouped into 20 clonal clusters by PFGE (Fig. 1), the remaining two isolates were not typable despite repeated attempts. The predominant cluster included four *bla*<sub>KPC-2</sub>-positive isolates distributed within the same hospital (the second affiliated hospital of Nanchang University), suggesting dissemination of clonal carbapenemase-producing *K. pneumoniae* in this facility. Four different clusters with two isolates each were also recovered from patients in this hospital. The remaining 15 profiles were represented by single isolates, and five isolates harbouring *bla*<sub>NDM-1</sub> had unique profiles indicating independent acquisition of these strains and the absence of cross-transmission between patients in the Nanchang area during the study period. In addition, strains of the same DNA profile were not isolated from patients receiving care in different hospitals, which underlined the fact that CRE did not spread between hospitals in the survey.

In conclusion, we report a high prevalence of *bla*<sub>NDM-1</sub> and PMQR determinants in CRE isolates from central China, as well as the co-existence in isolates of multiple resistance determinants in various combinations. Moreover, we provide the first reported co-existence of *bla*<sub>KPC-2</sub> and *bla*<sub>IMP-26</sub>. Co-existence of multiple resistance genes in CRE isolates contributes to MDR and poses formidable challenges for the treatment of clinically significant infections caused by these organisms. Effective surveillance and strict infection control strategies should be implemented to

prevent nosocomial infections caused by these MDR pathogens in China.

## ACKNOWLEDGEMENTS

This study was supported by grants from Wenzhou Municipal Science and Technology Bureau, China (Y20110043 and Y20100096) and Department of Education of Zhejiang province (Y201223071).

## DECLARATION OF INTEREST

None.

## REFERENCES

1. Tzouveleakis LS, *et al.* Carbapenemases in *Klebsiella pneumoniae* and other Enterobacteriaceae: an evolving crisis of global dimensions. *Clinical Microbiology Reviews* 2012; **25**: 682–707.
2. Rapp RP, *et al.* *Klebsiella pneumoniae* carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns. *Pharmacotherapy* 2012; **32**: 399–407.
3. Maltezou HC. Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance? *International Journal of Antimicrobial Agents* 2009; **33**: 405 e401–407.
4. Yong D, *et al.* Characterization of a new metallo-beta-lactamase gene, *bla*(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrobial Agents and Chemotherapy* 2009; **53**: 5046–5054.
5. Kumarasamy KK, *et al.* Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infectious Diseases* 2010; **10**: 597–602.
6. Leski T, *et al.* Multidrug resistance determinants from NDM-1-producing *Klebsiella pneumoniae* in the USA. *International Journal of Antimicrobial Agents* 2012; **40**: 282–284.
7. Rimrang B, *et al.* Emergence of NDM-1- and IMP-14a-producing Enterobacteriaceae in Thailand. *Journal of Antimicrobial Chemotherapy* 2012; **67**: 2626–2630.
8. Bonnin RA, *et al.* Dissemination of New Delhi metallo-beta-lactamase-1-producing *Acinetobacter baumannii* in Europe. *Clinical Microbiology and Infection* 2012; **18**: E362–365.
9. Shahcheraghi F, *et al.* First report of New Delhi metallo-beta-lactamase-1-producing *Klebsiella pneumoniae* in Iran. *Microbiology Drug Resistance* 2013; **19**: 30–36.
10. Chen Y, *et al.* Emergence of NDM-1-producing *Acinetobacter baumannii* in China. *Journal of Antimicrobial Chemotherapy* 2011; **66**: 1255–1259.
11. Fu Y, *et al.* Epidemiological characteristics and genetic structure of *bla*<sub>NDM-1</sub> in non-*baumannii* *Acinetobacter* spp. in China. *Journal of Antimicrobial Chemotherapy* 2012; **67**: 2114–2122.

12. **Zhou Z, et al.** Identification of New Delhi metallo-beta-lactamase gene (NDM-1) from a clinical isolate of *Acinetobacter junii* in China. *Canadian Journal of Microbiology* 2012; **58**: 112–115.
13. **Hu H, et al.** Novel plasmid and its variant harboring both a bla(NDM-1) gene and type IV secretion system in clinical isolates of *Acinetobacter lwoffii*. *Antimicrobial Agents and Chemotherapy* 2012; **56**: 1698–1702.
14. **Hu L, et al.** Emergence of blaNDM-1 among *Klebsiella pneumoniae* ST15 and novel ST1031 clinical isolates in China. *Diagnostic Microbiology and Infectious Diseases* 2013; **75**: 373–376.
15. **Dortet L, et al.** NDM-1, OXA-48 and OXA-181 carbapenemase-producing Enterobacteriaceae in the Sultanate of Oman. *Clinical Microbiology and Infection* 2012; **18**: E144–148.
16. **Kumarasamy K, et al.** Emergence of *Klebsiella pneumoniae* isolate co-producing NDM-1 with KPC-2 from India. *Journal of Antimicrobial Chemotherapy* 2012; **67**: 243–244.
17. **Karthikeyan K, et al.** Coexistence of blaOXA-23 with blaNDM-1 and armA in clinical isolates of *Acinetobacter baumannii* from India. *Journal of Antimicrobial Chemotherapy* 2010; **65**: 2253–2254.
18. **Wei Z, et al.** Coexistence of plasmid-mediated KPC-2 and IMP-4 carbapenemases in isolates of *Klebsiella pneumoniae* from China. *Journal of Antimicrobial Chemotherapy* 2011; **66**: 2670–2671.
19. **Zhang R, et al.** Outbreak of *Klebsiella pneumoniae* carbapenemase 2-producing *K. pneumoniae* with high qnr prevalence in a Chinese hospital. *Journal of Medical Microbiology* 2011; **60**: 977–982.
20. **Islam MA, et al.** Emergence of multidrug-resistant NDM-1-producing Gram-negative bacteria in Bangladesh. *European journal of Clinical Microbiology and Infectious Diseases* 2012; **31**: 2593–2600.
21. **CLSI.** Performance standards for antimicrobial susceptibility testing, 21th informational supplement (M100-S21). Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2011.
22. **Poirel L, et al.** Detection of NDM-1-producing *Klebsiella pneumoniae* in Kenya. *Antimicrobial Agents and Chemotherapy* 2011; **55**: 934–936.
23. **Queenan AM, et al.** Carbapenemases: the versatile beta-lactamases. *Clinical Microbiology Review* 2007; **20**: 440–458.
24. **Yu Y, et al.** Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China. *Journal of Infection* 2007; **54**: 53–57.
25. **Hu F, et al.** Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China. *Journal of Medical Microbiology* 2012; **61**: 132–136.
26. **Chen S, et al.** High prevalence of KPC-2-type carbapenemase coupled with CTX-M-type extended-spectrum beta-lactamases in carbapenem-resistant *Klebsiella pneumoniae* in a teaching hospital in China. *Antimicrobial Agents and Chemotherapy* 2011; **55**: 2493–2494.
27. **Dai W, et al.** Characterization of carbapenemases, extended spectrum beta-lactamases and molecular epidemiology of carbapenem-non-susceptible *Enterobacter cloacae* in a Chinese hospital in Chongqing. *Infection, Genetics and Evolution* 2013; **14**: 1–7.
28. **Girlich D, et al.** Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae. *Journal of Clinical Microbiology* 2012; **50**: 477–479.
29. **Castanheira M, et al.** Early dissemination of NDM-1 and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006–2007. *Antimicrobial Agents and Chemotherapy* 2011; **55**: 1274–1278.
30. **Wang Y, et al.** Characterization of a novel *Klebsiella pneumoniae* sequence type 476 carrying both bla KPC-2 and bla IMP-4. *European journal of Clinical Microbiology and Infectious Diseases* 2012; **31**: 1867–1872.
31. **Li B, et al.** First report of *Klebsiella oxytoca* strain coproducing KPC-2 and IMP-8 carbapenemases. *Antimicrobial Agents and Chemotherapy* 2011; **55**: 2937–2941.
32. **Jiang Y, et al.** Plasmid-mediated quinolone resistance determinants qnr and aac(6)-Ib-cr in extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in China. *Journal of Antimicrobial Chemotherapy* 2008; **61**: 1003–1006.